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Abstract 
Background: Hepatocellular carcinoma (HCC) usually affects patients aged 50–70 years but earlier onset (25–
40 years) may occur in hepatitis B endemic areas. 70–90 % of HCC develop on a background of cirrhosis. However, 
hepatitis B virus is directly oncogenic and can cause HCC in the absence of cirrhosis. This may represent a major cause 
of death from late diagnosis in resource-limited areas.
Case presentation: We report a black African family in which clinical diagnosis of HCC was made on two male sib-
lings in the south west region of Cameroon.
Conclusions: The highest risk for HCC may occur in families in which a hereditary component may be acting in 
concert with hepatitis B virus. In all cases of HCC, it is important to screen all first degree relatives to detect early and 
asymptomatic disease.
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Background
Hepatocellular carcinoma (HCC) is the fifth most com-
mon cancer worldwide, with more than 80  % of cases 
found in endemic areas of hepatitis B such as Africa 
or East Asia. The rising incidence in the West is due to 
increasing incidence of hepatitis C infection [1]. 70–90 % 
of HCC develop on background of cirrhosis. Hepatitis B 
is strongly associated (100 fold increase in risk) and alco-
holic cirrhosis is the commonest predisposing factor in 
the Western world. HCC occurs from the processes of 
chronic injury and regeneration (cirrhosis), and dyspla-
sia. Thus it usually affects patients aged 50–70 years [2]. 
However, hepatitis B virus (HBV) is directly oncogenic 
by incorporating into host genetic material and can cause 
HCC in the absence of cirrhosis. Thus an earlier onset 
(25–40 years) may be seen in endemic areas with earlier 
exposure [2–4]. The rare fibrolamellar variant in non-cir-
rhotic livers of young adults is a distinct entity not associ-
ated with hepatitis B infection. It is due to a heterozygous 
deletion on chromosome 19 that encodes a functional 
chimeric protein (DNAJB1-PRKACA) and characterized 
by being less aggressive with a normal alpha-fetoprotein 
(AFP) tumour marker and a female predominance [5, 6]. 
This is in contrast to conventional HCC which has a two-
fold to fourfold male predominance and occurs mostly in 
hepatitis B endemic areas [5]. Chronic hepatitis, cirrhosis 
of the liver, and HCC are known to be related to the hep-
atitis B surface antigen (HBsAg) positive rate suggesting 
the possibility of maternal transmission [4, 7]. The genetic 
abnormality that lead to HCC are not yet known but new 
genetic markers for diagnosis of hepatitis C related HCC 
have been demonstrated [8]. Only limited attention has 
been given to the role of primary genetic factors in HCC, 
but scattered anecdotal reports have identified famil-
ial aggregations of HCC (Table 1) [7]. Being rare familial 
fibrolamellar HCC has never been reported [6]. We pro-
pose that greater attention should be given to the role of 
primary genetic factors in HCC and that appropriate con-
sideration be given to interaction with environmental fac-
tors, such as HBV infection and aflatoxin exposures [6, 9].
Case presentation
A 35-year- old black African male presented with a 
3-month history of fever, and vague upper abdominal 
pain and progressive abdominal distension. This was 
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associated with rapid weight loss and anorexia. He also 
complained of difficulty in breathing because of the 
abdominal distension and could only sleep upright whilst 
sitting on a chair. He had no altered bowel habit and the 
stools and urine were of normal colour. There was no past 
history of jaundice or hepatitis and he did not smoke nor 
consumed alcohol. He had his normal childhood vaccina-
tions. The patient had been otherwise healthy and work-
ing for an airline hotel company. His younger brother 
had died 9  years previously, aged 24, from liver cancer. 
He had undergone an ‘open and close’ laparotomy for a 
large HCC on the left lobe. His symptoms and signs were 
almost the same as his sibling. He had moderate ascites 
but no stigmata of chronic liver disease. He suffered ago-
nizing pain in the terminal stage of the illness for which 
I palliated with narcotics. On examination of the sen-
ior brother 9 years after, apart from the respiratory dis-
tress the vital signs were within normal limits. He was 
not jaundice, but cachetic with gross ascites. There was 
severe bilateral pitting oedema of the legs with no palpa-
ble lymphadenopathy. There was a palpable non-tender 
nodular liver in the epigastrium but no peripheral stig-
mata of chronic liver disease such as leuconychia, palmar 
erythema, spider naevi, koilonychia, clubbing, jaundice, 
splenomegaly etc. An Upper gastrointestinal endoscopy 
in the early stage of his illness had revealed a healed 
antral ulcer but no oesophageal varices. An ultrasound 
scan confirmed ascites and a heterogenous mass of 9 cm 
in the left lobe of the liver. There were also few nodules 
in the right lobe with greatest diameter of 4  cm. There 
was no paraortic lymphadenopathy nor splenomegaly. 
The picture was consistent with HCC of a nodular type 
(Fig. 1). A chest X-ray was normal. A hepatitis screen for 
HBsAg and hepatitis C virus antibody (HCV Ab), along 
with human immunodeficiency virus (HIV) serology 
were negative. His haemoglobin level was normal (14 g/
dl). Liver function tests and serum biochemistry were not 
available but serum alpha fetoprotein was within the nor-
mal limits (1.14; normal range <8.5 ng/ml). A diagnostic 
ascitic tap demonstrated a yellowish exudate (protein 
50.3  g/lg/l) with predominantly lymphocytes consistent 
with malignancy or inflammation. He was put on a salt-
free diet and commenced on spironolactone 100 mg/day 
for 5 days which was increased to 200 mg/day thereafter. 
The malignant ascites remained refractory and a thera-
peutic paracentesis, with intravenous colloid replacement 
removed 3  l ascitic fluid per day for 3 days. His respira-
tory distress subsided and pitting oedema diminished. 
Just as we planned to do a percutaneous biopsy of the 
liver lesion, he deteriorated rapidly, with generalized 
weakness that required assistance with his oral feeding. 
He died a few days after. 
Conclusions
With respect to the natural history of hepatitis B, it takes 
10 years to develop chronic hepatitis, 20 years to develop 
cirrhosis and 30 years to develop HCC [3, 4]. The rapid 
development of ascites, increasing liver size or jaundice, 
in a patient with known cirrhosis would always suggest 
HCC [4]. Although there was no histological verifica-
tion, a clinical diagnosis of early-onset HCC was made 
in the two male siblings based on the fever, weight loss, 
right hypochondrial pain from nodular liver lesions and 
refractory ascites. There was no evidence of portal hyper-
tension as there was no stigmata of chronic liver disease, 
the ascites was exudative and the ultrasonic examination 
did not reveal an underlying cirrhosis [10]. The bilateral 
limb oedema was due to hypoalbuminaemia more from 
nutritional insufficiency than from liver dysfunction. The 
differential diagnosis would include the rare fibrolamellar 
Table 1 Familial hepatocellular carcinoma
Kaplan and Cole [20] 3 male adult siblings aged 64, 49 and 44
Hagstrom and Baker [21] 3 male siblings aged 11, 22 and 31
Denison et al. [22] Familial hepatoma on background micro-
nodular cirrhosis
Ohbayashi et al. [17] Familial clustering of asymptomatic carriers
Gilmore et al. [29] 3 or 4 male siblings in Chinese family
Lynch et al. [7] 2 familial aggregations in Costa Rica
Harvey et al. [23] 3 male siblings aged 33, 43, 46
Chang et al. [24] 2 pairs of young brothers (5 and 7years) and 
(9 and 7years)
Lok et al. [25] Morbidity and mortality from chronic hepati-
tis B virus infection in family members
Alberts et al. [26] Clustering of hepatocellular carcinoma in 
Alaska Native families
Weledji et al. [3]
BMC Research notes
2 male siblings aged, 24 and 35 in endemic 
area in Cameroon
Fig. 1 Transabdominal ultrasonography of liver showing multinodu-
lar HCC in left lobe and a nodular HCC with posterior enhancement 
in right lobe
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variant of HCC (FHCC) especially as the hepatitis 
screen was negative and it typically affects adolescents 
and young adults with often no coexistent liver disease 
nor history of hepatitis B infection [8]. Although FHCC 
mostly occurs in non-hepatitis B endemic areas, some 
cases have been reported in relatively endemic areas 
[11]. It is characterized by the lack of symptoms until 
the tumour is sizeable and is thus often advanced when 
diagnosed as in these siblings. Serum neurotensin, a new 
tumour marker for FHCC may discriminate it from HCC 
especially as a negative or normal value of alpha feto-pro-
tein tumour marker does not exclude an HCC [6]. Alpha 
feto-protein tumour marker is elevated in only 50–60 % 
of cases of HCC [12]. Global gene expression profiling 
revealed a small set of genes, SPINK 1, a secretory trypsin 
inhibitor as a potential HCC marker [13]. Although oper-
ator dependent, ultrasound scan is capable of detecting 
2  cm lesions, but further characterization by computed 
tomography (CT) or magnetic resonance imaging (MRI) 
is necessary [14]. Biopsy is usually not indicated except in 
specialist centres, or in inoperable cases. It is considered 
to carry a risk (1–2 %) of tumour seeding along the nee-
dle track, which may convert an operable tumour into an 
inoperable one [15]. A CT scan with or without biopsy 
of non-tumour liver is useful if in doubt of an underlying 
liver disease. CT chest  ±  bone scintigraphy would also 
exclude extrahepatic disease [3]. Tumour differentiation 
and vascular invasion are important predictors of sur-
vival after surgical resection or liver transplantation for 
HCC [16].
There must be a genetic basis for the aggressive liver 
malignancy occurring in two siblings during their early 
adulthood. It is unlikely to be by chance. The early age 
of onset especially in the 24-year old, harbour important 
implication for hereditary susceptibility to this lesion 
[6, 17]. Being in an endemic area it is very likely that the 
brothers were carriers of HBsAg. Even though the serol-
ogy was negative, occasionally infection without detect-
able serum HBsAg occurs. In these cases hepatitis B virus 
DNA (HBVDNA) and hepatitis B core antibody (HBcAb) 
tests would be mandatory [18]. In addition changes in 
HBsAg variants in carrier children before and after uni-
versal vaccination have been reported [19]. Up to 20  % 
of the population in these highly endemic areas may be 
asymptomatic HBsAg positive chronic carriers [1, 4]. 
Vertical transmission of the hepatitis B virus is prob-
ably a major reason for the high incidence of hepatitis 
B infection in the endemic areas, infants acquiring the 
virus from infected mothers in utero, at birth or shortly 
after birth (Fig.  1) [4]. With the impaired immunity of 
the baby compared with later life the infant is then at 
increased risk of developing persistent hepatitis B car-
riage, chronic active hepatitis, progressive liver damage 
and hepatocellular cancer [4]. The reason for some indi-
viduals becoming chronic HBsAg carriers, with develop-
ment of chronic liver disease or HCC in their adult years 
remains unclear. Genetic contribution may thus explain 
the presence of healthy or non-healthy carriers of HBsAg 
[4, 6]. The earlier onset of HCC in the younger sibling 
may indicate a greater genetic contribution to persis-
tent infection than in the older sibling. Familial occur-
rence of HCC was first reported by Kaplan and Cole 
which involved 3 male adult siblings aged 64, 49 and 44 
[20]. Hagstrom and Baker described HCC in 3 male sib-
lings aged 11, 22 and 31 and with no evidence of associ-
ated hepatic disease [21]. Denison et al. reported familial 
hepatoma on a background micronodular cirrhosis asso-
ciated with hepatitis-associated antigen [22]. Lynch et al. 
reported two familial aggregations of HCC from Costs 
Rica [7]. The maternal transmission of HBsAg and sus-
ceptibility to HCC as suggested by the pattern of involve-
ment, with the mother and three sons (one of a different 
father) affected was demonstrated by Harvey et al. [23]. 
Chang et al. reported fraternal hepatocellular carcinoma 
in young children in two families [24]. Alberts et  al. 
reported clustering of hepatocellular carcinoma in Alaska 
native families [25]. Lok et  al. Revealed the morbidity 
and mortality from chronic hepatitis B virus infection 
in family members of patients with malignant and non-
malignant hepatitis B virus—related chronic liver disease 
[26]. Gilmore et al. observed familial clustering of HCC 
in a Chinese family and concluded that HCC observed in 
3 or 4 male siblings even in the presence of hepatitis B 
infection seemed statistically unlikely to occur by chance 





Fig. 2 Family tree of two generations depicting carrier state com-
moner in males
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such as environmental (aflatoxin from fermented crops) 
exposure in certain parts of Africa and/or genetic factors 
may be involved [8, 28, 29]. Being rare, familial fibrola-
mellar hepatocellular carcinoma clustering has never 
been reported [7, 30, 31]. HCC-prone families of the type 
reported here could provide powerful models for study-
ing the preventive measures of a hepatitis B vaccination 
[32, 33]. It would seem prudent that hepatitis vaccina-
tion be given the highest priority to those individuals 
where the HCC yield is increased. The optimum timing 
for immunization in conjunction with the administration 
of hepatitis B immunoglobulin at a contralateral site is 
immediately after birth or within 12 h [34]. We suggest a 
more extensive investigation of the genetic hypothesis of 
HCC and its variant (FHCC).
Although not histologically verified because of the 
refractory ascites and minimal resources including 
autopsy, our observations document familial clustering of 
HCC. The highest risk for HCC may occur in families in 
which a hereditary component may be acting in concert 
with hepatitis B virus. In all cases of HCC it is therefore 
important to screen for genetic markers of HCC in all 
first degree family members and selected second degree 
relatives so as to detect early and asymptomatic disease 
(Fig. 2).
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